Feasibility/Acceptability of Attentional-Control Training in Survivors

Launched by CHILDREN'S NATIONAL RESEARCH INSTITUTE · Sep 1, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new type of training called EndeavorRx to see if it can help young survivors of pediatric cancers, specifically those who have had acute lymphoblastic leukemia or brain tumors, with their attention difficulties. The study involves children aged 8 to 16 who are at least one year out of treatment and are stable in their health. To participate, kids should not be on any stimulant medications for attention issues or must have been on a steady dose for at least 30 days. The study aims to find out if this training is easy to use and if families find it helpful.

Eligible participants will be asked to join the study and will have the chance to receive the attention training. The trial is currently looking for participants, so if you have a child who fits the criteria, it could be a great opportunity to explore support for attention challenges. It's important to note that children with certain conditions, like a history of seizures or significant mental health issues, cannot take part in the study. Overall, this trial hopes to provide valuable information on how to better support young cancer survivors facing attention difficulties.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 8-16 years at time of screening.
• • History of diagnosis of acute lymphoblastic leukemia (ALL) or brain tumor (BT).
• • At least 1 year from completion of planned therapy and stable from a disease standpoint.
• • Participating child and caregiver are fluent in spoken English.
• • Availability of a caregiver who is willing and capable of providing support and supervision during cognitive training.
• • Participating child is either not taking any prescribed stimulant medication for attention difficulties or has been prescribed a stable dose of stimulant medication for attention difficulties for at least 30 days prior to enrollment.
• • Only patients with a T-score ≥ 75th percentile on the CPT-3 Omission Errors scale or on the BRIEF-2 Cognitive Regulation Index will be randomized.
• Exclusion Criteria:
• • A history of photosensitive seizures.
• • A motor, visual, or auditory handicap that prevents computer use.
• • A mental health condition that precludes, or takes treatment precedence over, participation in the cognitive training.
• • Participants identified during the baseline assessment as having a full-scale IQ \< 80, as estimated by WASI-II (Vocabulary and Matrix Reasoning), will not be randomized.